N/A N=37 Physical Therapy Intervention for Puerperal Mastitis
Mastitis
Primary: Breast and Nipple Pain — 0; 0; 1 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=60 PEMF and PEC Blocks in Mastectomy Reconstruction Patients
Breast Cancer Female
Primary: Score on Visual Analog Scale (VAS) - 1 Hour Post-intervention — 6.64; 6.67; 4.62; 6.93 score on a scale
Phase 3 N=49 Postoperative Pain and Morphine Consumption After Mastectomy - Lyrica
Post-operative Pain
Primary: The Postoperative Opioid Requirement After Mastectomy — 9; 7.5 milligram (mg)
Phase 2 N=67 Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy
BRCA1 Mutation Carrier · BRCA2 Mutation Carrier · Ductal Breast Carcinoma In Situ
Primary: Mean Levels of Telapristone Acetate in Breast Tissue — 2.82; 103 ng/g
Phase 4 N=70 Perioperative Administration of Pregabalin for Pain After Mastectomy
Pain, Postoperative
Primary: Pain Scores (Verbal Numerical Rating Scale;VNRS) During Postoperative Hours. — 7; 5; 6; 5 Units on a scale
N/A N=162 Tumor: Breast Ratio Study
Breast Cancer · LCIS · DCIS
Primary: Quality of Life as Measured by the Breast Q — 61.9; 57.6; 74.2; 64.2 score on a scale
N/A N=70 Benefit of a Diagnostic MRI in Case of Pathological Nipple Discharge With Normal Mammography / Ultrasound
Breast Cancer
Primary: The Negative Predictive Value (PVV) of MRI
N/A N=20 Tactile Breast Imaging Sensor for Tumor Malignancy Characterization
Breast Cancer
Primary: Size Error in Millimeters — 0 milimeters
Phase 4 N=256 Effects of Tamoxifen in Premenopausal Women With Benign Breast Disease Not at High-Risk of Developing Breast Cancer
Benign Breast Disease · Fibrocystic Disease of Breast · Fibroadenoma
Primary: Number of Participants Analysed for Reduction in Lump Size ( 60% Reduction in Lump Size Considered to be a Satisfactory Response) — 63; 61; 54; 14 participants
Phase 2 N=37 Stellate Ganglion Block (SGB) For Women for Breast Cancer
Hot Flushes · Hot Flashes
Primary: Change in Number of Night Sweats From Baseline to 6 Months After Intervention. — 5.46; 10.09 night sweats/month
Phase 4 N=114 Arthralgia During Anastrozole Therapy for Breast Cancer
Early Breast Cancer
Primary: Number of Participants With New Events of Arthralgia — 37 Participants
N/A N=33 A Breast Support Intervention for Women With Breast Pain
Mastodynia
Primary: Patient Global Impression of Change (PGIC) — 55; 25 percentage of VMI/MI respondents
N/A N=26 Surgical Treatment of Post-surgical Mastectomy Pain Utilizing the Regenerative Peripheral Nerve Interface
Post-Mastectomy Chronic Pain Syndrome
Primary: Change in Pain Level — 6.9; 0.6; 4.4; 2.5 score on a scale
Phase 2 N=66 Study to Evaluate EB-001 in Reducing Musculoskeletal Pain
Musculoskeletal Pain
Primary: Subject's Assessment of Pain Using the Numeric Pain Rating Scale (AUC16h-96h) — 289.18; 341.78; 401.75; 290.55 units on a Scale*hours
N/A N=2,978 Molecular Breast Imaging and Digital Breast Tomosynthesis in Screening Patients With Dense Breast Tissue
Breast Carcinoma
Primary: Rate of Detection of Invasive Cancers — 9; 14 Participants
Phase 2 N=30 Denosumab and MRI Breast Imaging
Breast Cancer
Primary: Relative Change of ≥ 5% in Breast Density at 6 Months — 13; 8; 4 Participants — p=0.026
Phase 3 N=176 Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ
Breast Cancer · Dermatologic Complications · Radiation Toxicity
Primary: Mean Maximum Grade of Radiation Dermatitis by Treatment Arm. — 1.2; 1.3 Grade — p=0.18
N/A N=969 Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts
Breast Cancer
Primary: Diagnostic Yield — 3.2; 9.6; 10.7 cancers per 1000 women screened — p=.016
N/A N=28 Evaluation of Blood/Imaging Based Biomarkers, Aromatase Inhibitor Induced Musculoskeletal Syndrome
Aromatase Inhibitor Induced Musculoskeletal Syndrome (AIMSS) · Breast Cancer
Primary: Oxylipin Levels — 10.2; 12.1; 12.3 pg/mL — p=0.684
Phase 3 N=140 Evaluation in the Treatment of Neuropathic Pain Post Breast Surgery
Breast Cancer Patient
Primary: Change in Neuropathic Pain Score at 2 Months (Numeric Rating Scale 0-10) — 4.1; 4.6 units on a scale
N/A N=60 The Assessment of Molecular Breast Imaging (MBI) in Distinguishing Benign From Malignant Breast Disease
Breast Abnormalities
Primary: Specificity of MBI. Specificity is Defined as the Number of True Negatives/ Total Number of Negative Pathology Results. — 27 lesions
Phase 3 N=143 Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation
Invasive Breast Cancer
Primary: Percentage of Participants With Moist Desquamation — 66.7; 43.8 % of participants w/moist desquamation
Phase 2 N=28 Pilot Study of the Effect of Duavee® on Benign Breast Tissue Proliferation
Breast Cancer
Primary: Feasibility for a Larger Trial — 42; 28; 28 Participants
Phase 1 N=20 Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer
Breast Cancer
Primary: Maximum Tolerated Dose (MTD) — 10 milligrams
Phase 2 N=12 Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS
Breast Cancer · Ductal Carcinoma in Situ - Category
Primary: 18F-FES Uptake in DCIS — 1.43 SUV
N/A N=88 PECS II vs. MTP for Analgesia After MRM
Breast Neoplasm Female · Postoperative Pain Management
Primary: Post-operative Pain Severity Assessed by VAS at Hour-4 — 1.4; 2.2 score on a scale
N/A N=1,704 Radiologic Evaluation and Breast Density (READ)
Breast Cancer
Primary: Mammogram Recall for Additional Imaging — 11.3; 12.3; 9.8 percentage of women recalled
N/A N=1,638 Low Dose Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts
Breast Cancer
Primary: Cancer Detection Rate Per 1000 Women Screened, by Breast Density — 3.2; 12.0; 10.7; 0 cancers per 1000 women screened — p=<0.001
N/A N=314 Accelerated Intensity Modulated Radiation Therapy (AIMRT) to the Breast After Segmental Mastectomy
Breast Cancer
Primary: Number of Participants With Local Recurrence in Breast — 6 Participants
N/A N=22 Impact of Low-dose Tamoxifen on BPU
High Background Uptake on MBI
Primary: Change in Background Parenchymal Uptake (BPU) on Molecular Breast Imaging (MBI) — 0.0; -12 percent change in BPU